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Abstract 
Eicosanoids are important lipid mediators in the development of 
inflammation, progression of cancer and other pain associated diseases. 
Arachidonic acid (AA) is the precursor molecule for the synthesis of 
prostaglandin E2 and luekotriene B4 which is considered as pro-
inflammatory metabolites. Conversely, eicosapentanoic acid (EPA) is the 
substrate for the synthesis of anti-inflammatory metabolites such as 
prostaglandin E3 and luekotriene B5. 
In this study, the effects and influence of AA, EPA and inhibitor towards the 
synthesis of the four metabolites in cell cultures were investigated. AA-
derived metabolites showed minimal production when AA is the only 
substrate present in the cell culture media. Interesting, the levels of AA-
derived metabolites increased significantly in the presence of EPA. The 
results showed that EPA may play a role in the production of the AA-
metabolites. An understanding of the effects and interactions between the 
two molecules is important in establishing these metabolites as 
inflammatory biomarkers. 
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Chapter 1 
INTRODUCTION 
 
Fatty acids are organic molecules composed of a long hydrophobic unsaturated 
or saturated aliphatic chain to which is attached a hydrophilic carboxylic acid 
group (Fig. 1). The polyunsaturated fatty acids such as arachidonic acid (20:4n-
6) and eicosapentanoic acid (20:5n-3) synthesized from linoleic acid (18:2n-6) 
and alpha-linoleic acid (18:3n-3) respectively, are essential components in 
human diets and responsible for the production of eicosanoid metabolites (Innis, 
1991).  
 
Figure 1. Structure of a fatty acid containing 20 carbon chain (in black) and a 
carboxylic group (in red). 
 
Eicosanoids are compounds derived from fatty acid precursors generally 
containing 20-carbon atoms. They are also known as signaling molecules that 
exert complex control over many human and animal biological systems, mainly in 
the process of inflammation or immunity, and as messengers in the central 
nervous system. The networks of controls that depend upon eicosanoids are 
among the most complex in biological system (Coquette, et. al., 1992, Shapiro, 
et. al., 1994, Nieves and Moreno, 2006, Miles and Calder, 2007). 
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The eicosanoid synthesis takes place by means of three main pathways, namely 
a cyclic pathway characterized by the presence of cyclooxygenase (COX) 
enzymes, a linear pathway characterized by the lipoxygenase (LOX) enzymes 
and the cytochrome P450. These pathways can take place regardless of the 
availability of AA or EPA. The cyclic pathway is catalyzed by the action of the 
COX-1 and COX-2 which lead to the formation of prostaglandins, prostacyclins 
and thromboxanes (Fig. 2). The linear pathway is catalyzed by three different 
lipoxygenases specifically, 5, 12 and 15-lipoxygenases (5-LOX, 12-LOX and 15-
LOX respectively) and cytochrome P450 (P450) pathway  is catalyzed by P450-
dependent monooxygenases through a nicotinamide adenine dinucleotide 
phosphate (NADPH)-dependent mechanism.   These lypoxygenase enzymes 
along with P450 are responsible for the production of leukotrienes (catalyzed by 
5-LOX), hydroperoxyeicosatetraenoic acids (HPETEs) and hence into 
hydroxyeicosatetraenoic acids (HETEs) respectively and catalyzed by 12-LOX, 
15-LOX or P450. 
3  
  
 
Figure 2. Enzymatic oxygenation pathway of AA and EPA into eicosanoids 
metabolites (adapted from Arab, 2003). 
Prostaglandins, one of the major eicosanoid metabolites generated from the 
cyclooxygenase mediated pathway of the arachidonic acid and eicosopentanoic 
acid, are found in every animal tissue. It directs various physiologic and 
pathologic routes within the cells where they are produced in nearby cells in 
response to specific stimuli. Several, studies have demonstrated the role of 
prostaglandin in the cytoprotection of gastric mucosa (Zhang, et. al., 2009), renal 
physiology (Logan, et. al., 1992), gestation (Urquhart, et. al., 1997) and 
parturition (Rigby, et. al., 1998) under normal physiologic conditions. However, 
they are also associated with a number of pathological conditions such as 
bronchitis (Rigby, et. al., 1998), cancer (Chulada, et. al., 2000) and other kind of 
pathologies associated with inflammations. For example, depending on the 
interaction of prostaglandin E2 (PGE2) with one of the receptor in different cell 
types can exhibit pro or anti-inflammatory effects (Raud, et. al., 1988).  
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Other than prostaglandin, leukotrienes, the main products of the 5-LOX pathway, 
are also effective lipid mediators of inflammation. Research has revealed that 
overproduction of leukotrienes affects many diseases such as asthma (Wenzel, 
et. al., 1990), inflammatory bowel movement (Hawkey, et. al. 1992), rheumatoid 
DUWKULWLV *ȨUVHO HW DO  DXWRLPPXQH GLVHDVHs (Chen, et. al., 2009) and 
cardiovascular diseases (Freiberg, et. al., 2009). It follows that by inhibiting or 
controlling the synthesis of leukotrienes might pave the way for the treatment of 
several diseases.  
Fatty acids exhibiting the first double bond at the sixth carbon from the omega (or 
PHWK\OHQGDUHQDPHGRPHJDȦ-6) fatty acid. Arachidonic acid (AA), an Ȧ-6 
fatty acid (Fig. 3A), produces 2-series of prostaglandins and 4-series of 
leukotrienes when metabolized. Conversely, eicosapentanoic acid (EPA), an Ȧ-3 
fatty acid (Fig.3B), yields 3-series of prostaglandin and 5-series of leukotrienes 
as its breakdown products. 
 
A  
B  
Figure 3. Nomenclature of AA (A) and EPA (B) based on the position of the first 
double bond IURPWKHȦ-end. 
 
Since the discovery of this group of metabolites, many researchers including 
pharmaceutical industries still continue to have a great interest in this field of 
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research due to the role it portrays in pain and inflammation associated diseases. 
The intricacy of eicosanoids and the lack of powerful instruments for their 
analysis made the progression of information in this field not similar to the 
outburst of knowledge of other areas. Recent development in instrumental 
methods has created a great change in the field of eicosanoid research. Liquid 
chromatography with tandem mass spectrometry is regarded as a robust 
technique for quantifying eicosanoid metabolites simultaneously and considered 
as an information-rich technique as compared to nuclear magnetic resonance 
(NMR) and gas chromatography mass spectrometry (GC-MS) (Wenk, 2005). The 
predicaments regarding the elution of many metabolites at a similar retention 
time and identification of individual peaks were resolved by the aid of mass 
spectrometry .DWDMDPDD DQG 2UHãLþ  	 +X HW DO  :KHQ WKH
coelutants pass the liquid chromatography, through an appropriate interface, they 
are ionized and introduced into the mass spectrometer. The mass-to-charge ratio 
is measured and based on this ratio the coelutants can be identified and 
differentiated. With this instrumentation, changes in the eicosanoid mechanism or 
the pathway modulation of eicosanoid metabolites due to certain diseases can 
now be determined in complicated biological matrices. Changes in the metabolic 
profile can also be correlated with disease.  
Epidemiological studies revealed that AA-derived eicosanoids are generally pro-
inflammatory lipid mediators whereas EPA-acid derived eicosanoids are referred 
to as anti-inflammatory (Sastre, et. al., 2008). However, due to the controversies 
being raised regarding animal testing experiments, the shift to cell and tissue 
culture techniques become an alternative way for investigating the eicosanoid 
production (Akthar, et. al., 2008). Cell and tissue culture turn out to be preferable 
methods due to the feasibility to extensively control the physiochemical 
environment and physiological conditions and to perform biochemical monitoring 
and observations (Shaw, 1996). In addition, the cell and tissue culture methods 
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avoid the ethical and monetary issues like usage and killings of countless 
animals. 
Studies regarding eicosanoid production and synthesis on cell cultures are 
usually focused on either the LOX or the COX pathway. No studies have been 
published yet regarding how LOX and COX pathways affect each other towards 
the production of eicosanoids from both AA and EPA. Thus, it follows that 
simultaneous quantitative assessment of eicosanoid metabolites from 
cyclooxygenase and lypoxygenase pathways is vital in evaluating the behavior of 
the precursor molecules in the cell membrane and how these substrate 
molecules affects the synthesis of leukotrienes and prostaglandins.  
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1.2 Significance of the Study 
Previous studies indicated that EPA is a poor substrate for cyclooxygenase 
(COX) but can compete with AA by inhibiting its metabolism thus affecting the 
production of COX-derived metabolites such as prostaglandin E2 (PGE2) and 
prostaglandin E3 (PGE3). On the contrary, EPA is said to be a good substrate to 
lypoxygenase enzymes which follows that synthesis of the anti-inflammatory 
leukotriene B5 (LTB5) is favorable over the production of pro-inflammatory 
leukotriene B5 (LTB4). However, less information is available regarding the 
effects and interactions of prostaglandins and leukotrienes when both AA and 
EPA are present in a biological system and the effect of inhibiting the PLA2 and 
COX enzymes. The present study would provide preliminary evidence regarding 
how AA behaves in the cellular membrane in the presence of EPA and which 
pathway is more favored. Furthermore, this would shed new information on how 
the precursor molecules affect the production or synthesis of eicosanoids activity 
in systems where COX and PLA2 enzymes are blocked simultaneously.  
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1.3 Aims of the study 
The general aim of this research was to evaluate targeted eicosanoids 
biomarkers derived from arachidonic (AA) and eicosapentanoic (EPA) fatty acids 
in cell culture experiment by using liquid chromatography tandem mass 
spectrometry (LCMS-MS) and explore the applicability of some chemometrical 
strategies that could assist in evaluating the selected metabolites in the cell 
culture media.  
The specific objectives of the research were: 
1. To evaluate the influence of AA, EPA and inhibitor on the synthesis of pro 
and anti-inflammatory COX and LOX associated metabolites, specifically 
PGE2, PGE3, LTB4 and LTB5 in cell cultures system by using factorial 
experimental design and high performance liquid chromatography tandem 
mass spectrometry. 
2. To study the effect of inhibiting phospholipase A2 (PLA2) and COX 
enzymes in cells treated with EPA and/or AA. 
3. To study the behavior of EPA and AA towards the COX and LOX 
enzymes. 
4. To study the interaction of EPA, AA and inhibitor in cells towards the 
synthesis of prostaglandin and leukotrienes. 
5. To analyze and resolve the chromatographic and mass spectrum profiles 
by chemometrics.  
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Chapter 2 
LITERATURE REVIEW 
 
This chapter is divided into three sections. The first section describes important 
aspects involved in the chemistry and biology of eicosanoids; the second section 
introduces some analytical techniques generally used for the quantification of 
eicosanoids and the last section explains some chemometric approaches that 
could be used in the analysis of eicosanoids. 
2.1 Eicosanoids 
Eicosanoids were discovered and isolated from human semen by the Swedish 
Nobel laureate Ulf von Euler in 1930. It has been determined that they exist and 
are synthesized in every cell of the body and are referred as autocoids chemical 
messengers that do not move to other sites, but work right within the cells where 
they are synthesized. Eicosanoids are only active for a short period of time 
before they are modified into a non-functional form and are subsequently 
excreted from the body.  
 
2.1.1 Eicosanoids Nomenclature 
2.1.1.1 Prostaglandins 
The short form for prostaglandin is PG while the ensuing letter indicates either 
position of the double bond or the constituents of the 5-membered ring. Fig. 4 
shows how the positioning of the double bond in the ring system defines the 
names of PGA, PGB and PGC, while the positioning of the substituents in the 
ring defines the names of PGD and PGE, for instance. 
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Figure 4. Nomenclature of the prostaglandins based on their ring structures. 
The final subscripted number (e.g, PGE2 or PGE3) indicates the number of 
double bonds on the side chains. For example, PGE2 and PGE3 have the same 
substituent in their ring structures and 2 and 3 double bonds on the side chains 
respectively (Fig. 5). 
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Figure 5. Nomenclature of the prostaglandin based on their side chain 
structures. 
 
2.1.1.2 Leukotrienes 
The short form for leukotrienes is LT, the ensuing letter represents the 
substituent in the arachidic acid structure and the subscripted number represents 
the number of double bonds. For instance, LTB4 and LTB5 exhibit the same 
number of hydroxyl substituent (two hydroxyl substituents) and 4 and 5 double 
bonds along their arachidic structures, respectively (Fig. 6) 
 
Figure 6. Nomenclature of the leukotrienes. 
 
2.1.2 Eicosanoid Metabolism 
Eiocosanoids, such as prostaglandin (PGs), leukotrienes (LTs), thromboxanes 
(TXs) and lipoxins (LXs), are signaling molecules derived mainly from the 
enzymatic oxygenation of arachidonic acid (AA) and also from eicosapentanoic 
12  
  
acid (EPA) pathway (Fig. 7) (Wada, et. al., 2007). Since their discovery eight 
decades ago, countless studies have been conducted to establish the crucial part 
of eicosanoids in the metabolic pathway. Early investigations recognized the 
biochemical contribution of eicosanoids to vascular homeostasis, platelet 
aggregation and gastric mucosa protection (Boughton-Smith and Whittle, 1988). 
Nowadays, they are also involved in the regulation and control of various 
biochemical processes related to asthma, chronic pains, cancer (Chulada, et. al., 
2000 Larsson, et. al., 2004) and inflammation (Wenzel, et. al., 1990, Chen, et. 
al., 2009). 
 
Figure 7. Eicosanoid synthesis via the AA and EPA. 
 
2.1.2.1 Arachidonic Acid Metabolites 
The AA cascade (Fig. 8) is the major biosynthetic pathway for the production of 
the myriad eicosanoid metabolites. Cells exposed to various physiological and 
pathological stresses, release AA from the phospholipid membrane, catalyzed by 
the phospholipase A2 (PLA2).  Free AA then serves as a substrate for eicosanoid 
synthesis either through the COX or LOX described in Fig. 9 (Harizi, et. al., 
2008).  
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Figure 8. Arachidonic Acid cascade (adapted from Cayman Chemicals, MI, USA) 
 
Figure 9. Eicosanoids synthesis of arachidonic acid via COX and LOX pathway. 
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2.1.2.2 Eicosapentaenoic Acid metabolites 
Eicosapentanoic acid (EPA) is also a precursor molecule for the synthesis of 
eicosanoids. However, only fish are capable of synthesizing EPA whereas 
human get EPA from the fish they consumed in their diets.  
Although EPA and AA are structurally similar (both with 20 carbon atoms), they 
differ in the number and position of the double bonds. EPA has five double 
bonds, the first double bond located after the third carbon atom from the methyl 
end while AA is composed of four double bonds and the first unsaturation found 
after the sixth carbon from the methyl end. It has been reported that dietary EPA 
is incorporated into the cells by substituting AA from the cellular membrane 
(Nieves and Moreno, 2006) and that the same group of enzymes acting on AA 
can exert similar actions on EPA molecule to produce different eicosanoid 
metabolites. In this way, PLA2 releases EPA from the phospholipid bilayer 
membrane and converts EPA to 3-series of prostaglandins (PGE3) and 5-series 
of leukotrienes (LTB5) by the action of COX and LOX enzymes (Lee, et. al., 
1987). 
 
2.1.2.3 Biological Roles of Eicosanoids 
Most AA-derived eicosanoids are distinguished for their pro-inflammatory action 
as indicated by their high proportion during inflammation (Bagga, et. al., 2003). 
Studies also showed that PGE2 could be a link in the progression of cancer 
(Chulada, et. al., 2000). Leukotriene B4 (LTB4), another AA-derived product from 
the LOX pathway, is also associated in tumor cell adhesion leading to the spread 
of cancer cells in the body (Calder and Grimble, 2002).  
Although the majority of the AA-derived eicosanoid metabolites are referred to as 
pro-inflammatory agents, clinical studies showed that PGE2 is an exception 
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(Raud, et. al., 1988). The PGE2 also exhibits an anti-inflammatory property by 
inhibiting the 5-LOX and inducing the 15-LOX. The inhibition of 5-LOX results in 
low production of pro-inflammatory of leukotrienes (4-series species) while 
induction of 15-LOX enhances the formation of anti-inflammatory lipoxins 
(Schmitz and Ecker, 2008).  
The EPA-generated eicosanoids are regarded as potential anti-inflammatory 
mediator. However, EPA-derived leukotrienes and prostaglandins are less potent 
than the AA-derived. Leukotriene metabolites from the EPA via the 5-LOX 
pathway are less potent than their counterpart product from AA (Terano, et. al., 
1984). For instance, LTB5 is 30 times less bioactive than LTB4, the counterpart 
product from AA (Terano, et. al., 1984). Moreover, Hawkey, et. al. (1992) studied 
the effect of suppression of LTB4 synthesis by treating the inflammatory bowel 
disease patients daily with fish oil containing 4.5 g of eicosapentanoic acid for a 
year. The results showed that LTB5 concentration increased while those of LTB4 
decreased by approximately 50%. This result indicates that the anti-inflammatory 
effect of EPA works in three ways. Firstly, the EPA-generated leukotrienes acts 
as competitive inhibitors because they are less potent as compared from those 
coming from the AA precursor. Secondly, EPA suppresses LTB4 production 
through competition with AA on the lipoxygenase enzymes. Thirdly, EPA and its 
derivatives hasten inflammatory pathway reactions by inhibiting some steps in 
the lipoxygenase pathway (Hawkey, et.al., 1992).  
 
2.1.3 Arachidonic Acid in Cells and Tissue 
The level of free AA in unstressed cells is generally accepted as “low level”. 
Reports on the determination of AA are relatively few but usually the level of free 
AA is quantified using a mass assay. Using a mass per volume calculation, the 
level of esterified arachidonate in unstressed human plaWHOHWVaȝOYROXPHDQG
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reported amount is the average level for the whole cells but levels in subcellular 
compartments like the plasma membrane are expected to be higher.  
 
2.1.4 Eicosanoid Synthesis in Liver Cells 
Liver is a heterogenous tissue that is made up of parenchymal cells, the 
hepatocytes (epithelial cells) and at least four major types of non-parenchymal 
cells (messechymal cells), the Kupffer cells (resident macrophages), the 
perisinusoidal or stellate cells, the sinusoidal epithelial cells and the large 
granular lymphocytes (natural killer cells). About 65 % of the cells in the liver are 
parenchymal cells, which constitute the largest cell number and proportion of 
liver mass. The non-parenchymal cells are about 35 % which is 10% of the liver 
mass (Weibel, et. al, 1969 and Malik, et. al., 2002).  
The liver plays a vital role in body metabolism especially in eicosanoid synthesis, 
making it the preferred organ of choice for eicosanoid investigation. Bartolini, et. 
al. (1978) showed that in parenchymal rat liver cells 61 % of the intracellular fat 
was accounted for by the phospholipids. Furthermore, it was found that 7 % was 
free or in neutral lipids and 1 % was transformed into prostaglandins. On the 
other hand, non parenchymal cells  contains less arachidonate in the 
phospholipid membrane (22 %) but more free fatty acid (23 %) or converted AA 
into prostaglandins (4.3 %). The synthesis of prostaglandin is found to occur in 
rat liver homogenates, isolated hepatocytes and in both the parenchymal and the 
non-parenchymal liver cell fraction (Morita and Murota, 1980). 
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2.2 Analytical Techniques for Eicosanoids Quantitation 
Research studies showed that the eicosanoid synthesis is a web of complicated 
and interconnected interactions. Therefore, to be able to picture the changes 
created by blocking one pathway, there is a need to design a sensitive and 
reliable method that can identify and quantify simultaneously the eicosanoid 
metabolites.  
 
2.2.1 Immunoassays 
Conventionally, antibody based assays such as radio-immuno assays (RIA), 
have been used in quantifying different eicosanoids (Rocha, et. al., 1997). 
However, a lot of drawbacks are raised with regards to this technique. Aside from 
the few available antibodies for eicosanoids, there is also the danger of cross-
reaction of isomeric eicosanoids with various antibodies which can result in low 
selectivity leading to over or under estimation of the amount of metabolite 
present (Mesaros, et. al., 2009). Metabolite overestimation has been observed by 
Proudfoot, et. al. (1995) while studying the oxidation products of low density 
lipids. This study demonstrate that 8-epi PGF2 cross-reacted with PGE2 
metabolite by 4% which resulted to a much higher amount of PGE2 observed 
than the true value. Thus, this makes the use RIA both expensive and inefficient.  
A popular technique for the quantitative analysis of eicosanoids is the enzyme-
linked immunosorbent assay (ELISA). However, a number of problems are also 
associated with this technique such as the use of complicated procedures, low 
sensitivities, poor specificities, cross reactivities and complicated clean-up 
procedures for eliminating interfering substances in the sample matrix 
(Hishinuma, et. al., 2007). Il’yasova, et. al. (2004) have compared ELISA and 
GC-MS methods in determining the levels of PGF2-isoprostanes and found that 
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the estimated concentration by ELISA were 30 times higher than by GC-MS. This 
indicates clearly that ELISA could overestimate the levels of PGF2 in the sample. 
In addition, the procedure is limited to only to single product detection at a time. 
Unpublished studies at NIFES on the determination of PGE2 in cell culture media 
observed that the metabolite levels estimated by ELISA were 10 times higher 
than by LCMS-MS. 
 
2.2.2 Capillary Electrophoresis 
Capillary electrophoresis is also an appropriate method in some cases (Jin-Lan, 
et. al., 1998), but not applicable to the analysis of all types of eicosanoids. Aside 
from that, the technique has poor concentration sensitivity detection for the 
majority of analytes tested due to the limited sample-volume capacity of the 
capillary and the short (optical path length of the capillary when using on-column 
ultraviolet detection (Guzman, et. al, 2006).  
 
2.2.3 Gas Chromatography 
The evolution of gas chromatography-mass spectrometry (GC-MS) paved way 
for simultaneous analysis of multiple eicosanoids (Ribeiro, et. al., 1992 and 
Hammes, et. al., 1999). However, this technique requires a very tedious 
derivatization steps and consequently is quite time- consuming - especially for 
the analysis of many samples.  
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2.2.4 Liquid Chromatography 
The advent of high performance liquid chromatography tandem mass 
spectrometry (HPLC-MS), paved the way for the quantification of up to 60 
eicosanoids simultaneously as reported by Deems (2007). Based on the 
eicosanoids chemical and physical characteristics, eicosanoids can be isolated 
individually through liquid chromatography while collision-induced decomposition 
can yield distinct precursor or product transition that can be used in multi-reaction 
MS monitoring mode. Single or tandem LC-MS based methods have become 
one of the most powerful techniques for determining eicosanoids in cell cultures 
due to their high sensitivity, high selectivity and simplicity of sample preparation 
(Deems, 2007). Cao, et. al. (2009) developed a method based on LCMS-MS 
technique for determining PGE2 and PGD2 production in cell culture supernatants 
and other biological fluids. This study achieved a limit of detection of 20 pg/mL 
and an inter-day and intra-day coefficient of variation lower than 5%. 
Furthermore, Araujo, et. al. (2008) devised a much simpler method involving 
LCMS-MS protocol by replacing the conventional time-consuming sample 
preparation of cell cultures with direct injection of redissolved cell culture media 
into the LCMS system and limits of detection and quantification for Williams’ 
medium E and L-15 medium of 0.5 and 1 ng/mL, respectively. In addition, 
Blewett, et. al. (2008) was able to develop also an LCMS method that can 
separate and quantitate 23 different eicosanoids from all the three oxidative 
pathways. The limit of detection ranges from 1.6-174.0 pg/mL for the 23 different 
metabolites, which is sensitive enough to quantitate endogenous levels of 
eicosanoids. However, a leukotrienes yeilded very poor chromatographic peak 
shapes due to the presence of protonated amino acid moieties on the cys-LT 
(Blewett, et. al., 2008).   
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2.3 Chemometric Approaches 
2.3.1 Design of Experiment 
During the past decades the investigative approaches to biological problems 
have markedly diversified. This diversification has been cause in part by the 
introduction of methods from mathematics, statistics and chemistry such as 
factorial design, principal component, factor analysis, etc (Kwak, et. al., 2006, 
and Benoit, et. al., 2007) . Since the biological processes involved a wide variety 
of factors, screening approaches are regarded as an important component in 
experimental design procedures. This is the first stage to efficiently assess the 
factors influencing an analytical system under investigation.  
Different screening approaches for assessing the influence of several factors 
have been reported (Araujo and Brereton, 1996). The first step is to identify a 
region of study for each factor under consideration. The chosen region is an 
experimental sensible region which is referred to as the experimental domain. 
The results outside this chosen region cannot be classified as valid. The second 
step is to choose a design. One class of experimental design that can be used to 
study a biological system is a factorial design. Using this design, the 
experimenter can vary simultaneously the different factors included in the 
experiment in a systematic way. Moreover, it can be use to estimate the 
influence of the factors under study along with the interaction (Deming, 1987). In 
single factorial design, only one independent factor is involved in which the factor 
is manipulates at multiple levels and the effect of the factor is based on the 
results of the analysis of variance. This design can be used when running 
experiments with less time or material available but it is very limited in scope. 
However if two or more factors are of equal interest, two-level factorial design is 
more applicable and a popular choice among experimenters. Morgan (1995) 
mentioned that this design allows the experimenter to have a glimpse of the 
effects of the factors involved in a relatively few runs. Aside from that, the results 
21  
  
are easy to evaluate and can provide major trends even though only a small 
region of the factor space is under investigation. Choosing a response is the third 
step in screening approach. The chosen response should be easy to quantify 
such as extraction efficiency, peak area or signal height. Hence, it is important to 
select an appropriate measurement of response to avoid formulating inaccurate 
conclusion. The last step is to build a mathematical model relating the response 
to the factors involved (Araujo & Brereton, 1996). Usually, the raw data are not 
use, instead coded factors are utilized. Typically, the lower level is denoted by -1 
and the higher level by +1. 
 
2.3.2 Multivariate Curve Resolution 
Peak resolution and alignment are the most often encountered problems when 
analyzing LCMS data set (Scott, 1995). Although experimental optimization 
methods are usually employed, their contribution in improving the 
chromatographic resolution cannot be regarded as improvement (Massart, et. al., 
1988).  
The most common approaches available for unbiased preprocessing of 
information from LC-MS data are peak detection, curve resolution or 
deconvolution and summing of data to obtain a total mass spectrum for each 
sample. A peak detection algorithm is used to detect all peaks in the data above 
the specified noise threshold. Peak area and peak height are then used for 
quantitatitation while the retention time and m/z are used for identification 
(Plumb, et. al., 2003). Curve resolution and deconvolution are done to resolve 
overlapping peaks of the chromatographic and spectral profiles. The areas of 
chromatographic profiles become the basis for quantitative measure of the 
compound while the spectral profiles and retention times are used for 
identification purposes (Idborg-Björkman, et. al., 2003). Summation of data is 
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done by combining the whole chromatograms or first by dividing the 
chromatogram into segments and then combining all the segments before 
subjecting to multivariate analysis (Plumb, et. al., 2002). 
Resolution methods can be classified into three kinds: iterative, non-iterative and 
hybrid methods. Iterative methods begin with guessing or defining an initial set of 
profiles. Then non-negativity and unimodality constraints are imposed during the 
iteration process. Iterative target transformation factor analysis (ITTFA) and 
alternation regression (AR) belongs to this category (Maeder and Neuhold, 
2007). They are simple to use but the results of these methods are dependent 
upon the starting vectors. Better results can be obtained if the separation power 
of chromatography is used to localize key spectra that are either pure, or whose 
signal is dominated by one analyte (Shen, et. al., 2001). 
The non-iterative methods follow the elution of analytes by rank analysis of 
evolving matrices (Shen, et. al., 2001). The evolving factor analysis (EFA) 
(Séquaris and Koglin, 1987), window factor analysis (WFA) (Malinowski, 1992), 
and heuristic evolving latent projections (HELP) (Liang, et. al., 1992) belong to 
this cluster. In non-iterative methods, the corresponding concentration and 
spectral profiles can be estimated when the elution window of each analyte is 
obtained. However, unresolved background and heterosedastic noise are just a 
few factors that affect the matrix rank (Liang, et. al., 1993, Wang, et. al., 1996 
and Shen, et. al., 2000). 
Hybrid procedures are combination of both iterative and non-iterative features. 
This group includes the automatic window factor analysis (AWFA) (Malinowski, 
1996) and Gentle procedure (Manne and Grane, 2000). The two methods 
overcome the drawbacks of iterative and non-iterative procedures.  
Gentle procedure, as proposed by Manne and Grande (2000), involves removal 
of negative region, estimation of elution window, minimization of concentration 
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profiles outside the elution windows and checking the quality of resolution to 
estimate the concentration and spectral profile. 
 
Recently, software package based on Gentle principle for multivariate curve 
resolution become available. It is iterative approach in solving Eq. 1 where X is 
the data matrix obtained for a sample, C is the true chromatographic profile, S is 
the spectra for all components and E is the residuals. 
ECSX T        (1) 
 
MS Resolver™ (Pattern Recognition System, Bergen, Norway) is designed to 
resolve multiple component data from hyphenated instruments such as mass 
spectroscopy data. Unlike the Xtricator (another curve resolution software from 
the same company) which depends heavily on interaction with the software user, 
MS Resolver™ is a fully automated resolution package. The advantages of using 
MS Resolver™ are the reduction of analysis time, capability to resolve data from 
samples containing more than 400 components and the possibility to work on 
more complex data. Spectral similarity and retention times are used by MS 
Resolver™ to match the resolved components from different samples 
automatically. The integrated chromatographic areas for each compound in each 
sample are then placed in a predictor matrix, without any user interaction. This 
matrix can be exported and used in calibration and regression against an 
external response variable. 
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Chapter 3 
EXPERIMENTAL 
 
3.1 Materials and Reagents 
Dulbecco’s modified eagle medium (DMEM), L-15 medium, antibiotic antimycotic 
solution, flunixin meglumine, N-(2-phenylethyl)indomethacinamide, arachidonic 
acid (AA), eicosapentanoic acid (EPA), leukotriene B5 (LTB5) were from Sigma-
Aldrich (St. Louis, MO, USA).  
Prostaglandin E2 (PGE2), prostanglandin E3 (PGE3), leukotriene B4 (LTB4) were 
from Cayman Chemicals (Ann Arbor, MI, USA).  
GlutaMax was from Gibco-BRL (Cergy-Pontoise, France). 
Penicilline-streptomycine-amphotericine was from BioWittaker (Petit Rechain, 
Belgium). 
Acetonitrile and formic acid were from Merck (Darmstadt, Germany). 
De-ionized water was purified in a Milli-Q system (Millipore, Milford, MA). 
The 12 well plates used were from Corning (New York, USA). 
Non-parenchymal and head kidney cells were isolated and cultured from Wistar 
rat liver and Atlantic cod and kindly donated by Dr. Zhen-Yu Du and Dr. Elisabeth 
Holen from the National Institute of Nutrition and Seafood Research (NIFES). 
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3.2 Culturing Protocol 
3.2.1 Non-Parenchymal Cultures 
Non-parenchymal cells isolated from Wistar rats and almost free of Kupffer cells 
were seeded to two 12-well dishes at approximately 5 × 106 cells per unit density. 
The attached cells were pre-incubated in Dulbecco’s modified eagle medium 
(DMEM) containing 10 % v/v fetal bovine serum and 1.0 % v/v antibiotic 
antimycotic solution for three hours at 37 Û&XQGHUKXPLGLILHGDWPRVSKHUH (5% 
CO2, 95% air). After the pre-incubation period, DMEM was removed and the 
attached cells were washed with DMEM medium alone to remove unattached 
and viable cells. The incubation period started by adding the specified volume of 
ȝ0$$6LJPDȝ0(3$6LJPDor inhibitor as indicated in Table 2 and 
was made up to 1mL total volume by adding DMEM with 10 % v/v bovine serum 
albumin (BSA) and 1% v/v antibiotic. The cells were then incubated for 48 hours 
without changing the media.  
 
Table 1. Volumes of the AA, EPA and Inhibitor Added to each Wells 
 
Volume added in each treatment in mL 
1 2 3 4 5 6 7 8 
ȝ0$UDFKLGRQLF$FLG 0 0.45 0 0.45 0 0.45 0 0.45 
ȝ0(LFRVDSHQWDQRLFAcid 0 0 0.45 0.45 0 0 0.45 0.45 
Inhibitor (mixture of COX 
and PLA2 inhibitors) 
0 0 0 0 0.1 0.1 0.1 0.1 
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3.2.2 Head Kidney Cultures 
Head kidney cells isolated from Atlantic cod (800-1000g) were seeded into a 12 
well plate with a density of 3 × 106 cells per well. A volume of 2 mL of L-15 
medium consisting of 1 % glutaMax, 1 % penicilline-streptomycine-amphotericine 
and 10% bovine serum was added to each well. The cells were incubated at 9 ºC 
in a normal atmosphere incubator for 24 hours without changing the medium. 
 
3.3 HPLC-MS Sample Protocol 
After incubating non-parenchymal cells and head kidney cells for 48 and 24 h 
respectively, 1 ml of the DMEM media was centrifuged at 3000 g for 10 min at 4 
ºC. An aliquot of 500 ȝ/ RI VXSHUQDWDQW LV FROOHFWHG DQG YDFXXP GULHG  in a 
RapidVap vacuum evaporation system (Labconco, Kansas, MO). An aliquot of 
ȝ/RIDFHWRQLWULOHZDVDGGHGWRWKHGULHGVDPSOHYRUWH[-mixed for 1 minute 
and the supernatant collected. The collected supernatant was evaporated to 
dryness under nitrogen DW URRP WHPSHUDWXUH DQG UHFRQVWLWXWHG LQ  ȝO RI
acetonitrile, vortex-mixed for 30 seconds and submitted to LCMS/MS. 
The aforementioned method (Araujo, et. al., 2008) permitted the injection of the 
redissolved cell culture media into HPLC-MS. The selection of this method was 
based on its several advantages. For instance, there is no need for 
derivatisation, degradation, solid-phase extraction, liquid-liquid extraction, thin 
layer chromatography or a combination of all these steps prior to HPLC-MS/MS 
analysis. In addition, it possesses low limits of detection and quantification in cell 
culture media (0.5 and 1 ng/mL respectively) and recovery percentages close to 
100%. 
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3.4 External Standards 
The quantification of PGE2, PGE3, LTB4 and LTB5 in the media was carried out 
by means of external calibration curves (0-500 ng/mL). The standards were 
mixed in acetonitrile to a final concentration of 700 ng/mL of each metabolite and 
the calibration curve was prepared as follows. The aliquot of the mixture were 
collected to yield the nominal concentrations between 0-500 ng/mL and a total 
YROXPH RI  ȝ/. The calibration curve standards in acetonitrile solution were 
prepared in triplicates and evaporated to dryness under a stream of nitrogen at 
URRPWHPSHUDWXUH$OLTXRWVRIȝORIIUHVKFXOWXUHPHGLXPZLWKQRGHWHFWDEOH
levels of PGE2, PGE3, LTB4 and LTB5 were added into each set of vials and 
vortex-mixed for 2 min and submitted to LCMS-MS. 
 
3.5 High Performance Liquid Chromatography tandem Mass Spectrometry 
The high performance liquid chromatography system used was an Agilent 1100 
series LCMS ion trap detector (SL model) equipped with electrospray interface 
(ESI), a quaternary pump, degasser, auto-sampler, thermo-stated column 
compartment, variable-wavelength UV-GHWHFWRUDQGȝO LQMHFWLRQYROXPH7KH
separation was performed using Zorbax Eclipse-C8 reversed phase column 
(Agilent, Palo Alto, USA) with dimensions of 150 mm × 4.6 mm × 5 ȝP DQG
maintained at 40 Û&FROXPQRYHQWHPSHUDWXUH$QLVRFUDWLFPRGHVROYHQWV\VWHP
was employed using acetonitrile with formic acid of 0.1% (v/v) mobile phase, and 
flow rate and UV wavelength set at 0.2 mL/min and 254 nm, respectively. The 
VDPSOH LQMHFWLRQ YROXPH ZDV  ȝ/ $ QHJDWLYH LRQ PRGH (6, ZDV XVHG DV
ionization source and the ion optics responsible for getting the ions in the ion-trap 
were controlled by using the Smart View option with a resolution of 13000 
m/z/sec (FWHM/m/z = 0.6-0.7). The nebulizer gas used was nitrogen with a flow 
of 8 L/min, pressure 350 psi and temperature of 350 Û&7KHPDVVSURILOH s were 
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obtained using multiple reaction monitoring (MRM) with scan mass range of 50-
1000 m/z. The total time it required for each sample run was 60 minutes. Data 
acquisition and pre-processing were done using the Chem Station for LC/MSD 
version 4.2 from Agilent and converted into CDF files. The transitions monitored 
are indicated in Table 2. 
 
Table 2. Transition Monitored Among Eicosanoid Metabolites 
Eicosanoid 
Metabolites 
Parent Ion 
Molecular 
weight, [M-
H]- 
Product Ion Molecular Weight 
[M-H]-Æ 
[M-H2O-H]- 
[M-H]-Æ 
[M-2H20-H]- 
[M-H]- Æ 
[M-2H2O-CO2-H]- 
[M-H]- Æ 
[M-H2O-CO2-H]- 
PGE2 351 333 315 271  
PGE3 349 331 313 269  
LTB4 335 317   273 
LTB5 333 315   271 
 
3.6 Experimental Design 
A two-level factorial design involving three variables was used in this study to 
determine the production of PGE2, PGE3, LTB4 and LTB5 from non-parenchymal 
cell cultures. The variables were AA, EPA, and an inhibitor (Inh) that block 
simultaneously the action of the COX and PLA2 enzymes. The levels analyzed 
were absence and presence of the previously mentioned three variables and 
denoted by a negative (-) or a positive (+) sign. The number of experiments was 
dictated by the expression 23= 8 experiments. The eight experiments allowed 
determining the effects of AA, EPA and inhibitor along with their interactions. All 
possible combinations are detailed in Table 3 and were measured in triplicates. 
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The differences between the variance of treatments were evaluated using single 
factor ANOVA at a 95 % confidence limit. 
The main effects and interaction effects were evaluated using the Minitab® 
15.1.30.0 (Minitab® Inc, PA, USA) statistical software package. 
 
Table 3. Treatment Employed to the Non-Parenchymal Cell Cultures 
Treatment 1 2 3 4 5 6 7 8 
AA - + - + - + - + 
EPA - - + + - - + + 
Inhibitor - - - - + + + + 
 
3.7 MS Resolver™ and Chromatogram Integration 
Data obtained from LC-MS/MS systems are known as two-way data and every 
sample is characterized by a matrix. The rows and columns of such matrices 
contain special meanings as illustrated in Fig. 10. A time direction and a mass 
direction are denoted for a given matrix. Each row signifies the mass spectrum 
recorded at a specific time. Graphical illustration of the row vector gives a mass 
spectrum of analytes that eluted at a particular retention time. Similarly, plotting a 
column vector results in a chromatogram profile of the analytes that has a 
fragment at that particular mass/charge ratio. In cases of complex samples 
containing different components, separation is difficult and overlapping is 
unavoidable. For this kind of problem MS Resolver™ is a great help. 
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Figure 10. Data matrix for a typical LC/MS data. 
MS Resolver™ software (Pattern Recognition System, Bergen, Norway), a fully 
automated software package, was used for curve resolution process. The CDF 
files coming from the LC-MS/MS system were imported into the software using a 
resolution of one mass number. The size of the data sets was reduced by 
creating a subset and saving parts of the original data set under a different name.  
For every metabolite extracted ion chromatogram profiles, data subsets were 
created by selecting the mass/ratio of a particular metabolite of interest. From the 
create subset data, all values in the time point rows option were selected while in 
the mass number option one particular m/z value (PGE2 = 333, PGE3 = 331, 
LTB4 = 317 and LTB5 = 315) was chosen as detailed in Fig. 11. The resulting 
subset yielded a chromatogram plot with only one mass number. 
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Figure 11. Schematic procedure for creating a subset from a given LCMS data. 
Resolved chromatogram profiles were exported and saved as MATLAB files. The 
area of the chromatogram profiles was further integrated using the trapezoidal 
method of integration coded in MATLAB 7.9.0.529 (R2009b) (The Mathworks, 
MA, USA). Microsoft® Excel 2007 SP-2 was used to calculate the mean, the 
standard error of the mean and the standard deviation. Data were analyzed and 
displayed using the Data Analysis Tool of Microsoft® Excel 2007 SP-2.  
Both information on the m/z direction and retention time direction are taken into 
consideration by using the MS Resolver™ software.  
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Chapter 4 
RESULTS AND DISCUSSION 
 
The discussion of results is divided into four parts. The first part is a brief 
discussion of the eicosanoid metabolites LCMS-MS spectra, second part deals 
with the application of MS Resolver™ in resolving the eicosanoid chromatogram 
and spectral profiles, third part focuses on the experimental design in 
determining the effects of AA, EPA and inhibitor on eisosanoid synthesis and the 
last part discusses the eicosanoid synthesis using different cell to support the 
data obtained from non-parenchymal cells. 
 
4.1 Identification of the LCMS-MS Profile of Eicosanoid Metabolites 
 
The PGE2, PGE3, LTB4 and LTB5 external standards (700 ng/mL) prepared 
individually in acetonitrile were submitted to LCMS-MS to evaluate their elution 
times and behavior of their mass spectra. The mass spectrometric data were first 
collected in auto-scan mode from m/z 50-1000 from 0-20 min, in negative ion 
mode to obtain the full information about the behavior of the mass spectra of the 
four particular eicosanoids. Inmediately after, the eicosanoids metabolites were 
monitored using multi-reaction mode so that a high response of the analyte of 
interest will be obtained. From the chromatogram of a standard mixture (Fig 12), 
it was found that only one peak exist instead of the expected four different peaks. 
By selecting the EIC chromatogram of the PGE2, PGE3, LTB4 and LTB5 
metabolites and overlaying the four chromatogram profiles, severe overlapping of 
chromatogram peaks was observed (Fig. 13). The elution times were 8.5, 8.0, 
8.3, and 8.0 min for PGE2, PGE3, LTB4 and LTB5, respectively.. 
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Figure 12. TIC chromatogram of the standard mixture collected in MRM mode. 
 
Figure 13. EIC chromatogram of the standard mixture collected in MRM mode. 
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The tandem mass spectral profiles of the four metabolites are shown in Figs. 14-
17.  The spectral profile of PGE2 (Fig. 14) shows the deprotonated precursor ion 
at m/z = 351 along with its characteristic massfragments at  m/z values 333, 315, 
and 271. The resulting fragments are due to the subsequent loss of two water 
molecules and a carboxyl group from the deprotonated PGE2 precursor ion. A 
similar m/z transitions patterns were also observed from the PGE3 ion (Fig. 15) 
giving m/z 331, 313, 269 as the fragment ions. On the other hand, the leukotrines 
spectra (Figs. 16-17) are characterized in general by the fragments [M - H2O - H]- 
and [M-H2O-CO2-H]- from the precursor ions LTB4 and LTB5. 
For quantitative evaluation, the first m/z transition of every metabolite, 
corresponding to the loss of a molecule of water (m/z 333, 331, 317 and 315 for 
PGE2, PGE3, LTB4 and LTB5 respectively) was used because they exhibit the 
highest intensity and abundance. 
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Figure 14. MRM transition of PGE2 from m/z 351Æ 333, 315, 271 m/z. 
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Figure 15. MRM transition of PGE3 from m/z 349Æ 331, 313, 269 m/z. 
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Figure 16. MRM transition of LTB4 from m/z 335Æ 317, 273 m/z. 
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Figure 17. MRM transition of LTB5 from m/z 333Æ 315, 271 m/z
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4.2 Application of MS Resolver™ to LCMS-MS Data 
The use of hyphenated technique such as LCMS is a now a leading technique in 
generating metabolite profiles from complex biological samples due to its high 
sensitivity (Panchuad, et. al., 2005, Kempen, et. al., 2001, Yue, et. al., 2007 and 
Yan, et. al. 2005). The use of LC-ESI-MS-MS is widely accepted as a reliable 
technique for characterization and quantification of eicosanoids  (Margalit, et. al., 
1996, Newman, et. al., 2002 and Schmelzer, et. al., 2005). However, due to the  
similarity in structure of the various eicosanoids and their chemical 
characteristics, peak overlapping pose a major problem in acquiring information-
rich data. Hence, there is a need for a systematic approach to extract information 
from LCMS data such as multivariate curve resolution or deconvolution. 
In this study the capability of MS Resolver™ (Pattern Recognition System, 
Bergen, Norway), an automated curve resolution software package, to resolve 
spectral and chromatographic profiles of AA and EPA derived eicosanoids was 
explored. The TIC of one of the samples is shown in Fig. 18 where it is evident  
the overlapping of the mass profiles at different time points. The original 
chromatogram profiles of the metabolites under study usually contain 
approximate 170 retention times and 960 mass numbers (Fig. 19). From the plot 
(Fig. 19), it is also evident that most of the components in the sample elute 
approximately between the regions of 450-700. Since the chromatograms 
profiles were monitored via MRM mode, the m/z value of interest is already 
known. With this, modification in the steps of MS Resolver™ the analysis was 
done. Instead of dealing with the whole LC MS data set, a subset was created by 
selecting the m/z value of interest over the given set of time. After creating the 
subset, a chromatogram profile containing only one m/z value was obtained (Fig. 
20). Unlike the previous untreated data, the processed chromatogram exhibits a 
defined peak of the component which is easy to quantify using the trapezoidal 
method of integration coded in MATLAB. 
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Figure 18. a. TIC chromatogram of a sample depicting the different mass 
number found at different time points (plots b-e). 
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Figure 19. Original chromatogram profile obtained from LCMS data 
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Figure 20. The chromatogram after extracting a specific m/z value using 
MS Resolver. 
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4.3 Two-Factorial Experimental Design 
The eicosanoid synthesis in vitro or in vivo is dependent not only to the pre-
existing AA in the cellular membrane but also to other factors such as added AA 
and EPA in to the biological system. To explore further the influence of added AA 
and EPA in non-parenchymal rat liver cells, a 2-level three-factor design (23) was 
carried out. The studied variables were AA, EPA and inhibitor of both 
cyclooxygenase (COX) and phospholipase A2 (PLA2) enzymes.  The levels were 
the presence or absence of the factors. The full 23 factorial design allows 
estimating: 
1. The in vitro effect of AA and EPA (either individually or in combination) on 
the production of their COXs (PGE2 and PGE3) and LOXs (LTB4 and 
LTB5) metabolites. 
2. The in vitro effect of COX/PLA2 inhibitor (either individually or in 
combination with AA and EPA) on the production of AA and EPA related 
COXs and LOXs metabolites. 
 
4.3.1 Eicosanoids Responses 
The non-parenchymal rat liver cell production of AA and EPA derived 
eicosanoids, PGE2/LTB4 and PGE3/LTB5 respectively and released in the 
medium was determined by using the 2-factorial experimental design and LC-
MS-MS. The experimental response selected to assess the effects of the 
variables and their interactions was the average metabolite concentration 
expressed in ng/mL and calculated by means of the external standard calibration 
curve. The estimated concentrations for the various prostaglandins and 
leukotrienes (PGE2, PGE3, LTB4 and LTB5) are presented in Table 4. The 
positive (+) and negative (-) signs denotes the presence and absence of the 
variables in the treatments, respectively. 
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Table 4. Eicosanoids Mean Response obtained using 23 Factorial Experimental 
Design. 
Treatment AA EPA INH 
Response in ng/mL Concentration 
PGE2 PGE3 LTB4 LTB5 
1 -1 -1 -1 15.2 ± 1.5 7.3 ± 1.0 8.4 ± 0.6 12.1 ± 0.4 
2 1 -1 -1 15.4 ± 2.0 11.5 ± 1.0 12.5 ± 3.2 14.0 ± 1.8 
3 -1 1 -1 19.7 ± 4.4 19.2 ± 2.7 185.1 ± 27.8 13.1 ± 0.1 
4 1 1 -1 22.2 ± 6.1 27.3 ± 3.5 191.8 ± 29.1 16.0 ± 1.8 
5 -1 -1 1 18.6 ± 3.2 14.1 ± 3.5 30.8 ± 6.3 5.6 ± 1.0 
6 1 -1 1 14.8 ± 0.7 6.3 ± 2.9 23.8 ± 7.1 10.8 ± 0.8 
7 -1 1 1 22.4 ± 4.2 33.2 ± 19.6 363.3 ± 98.8 14.9 ± 3.4 
8 1 1 1 28.2 ± 15.4 20.8 ± 0.4 333.8 ± 183.7 15.6 ± 8.7 
 
 
4.3.2 Estimation of Effect 
The main effects of the variables under study (AA, EPA, Inh) were computed as 
follows: firstly, the product of the variable by the response (variable × response) 
is performed, secondly the average responses at low and high level (-1 and +1) 
are estimated from the resulting product and thirdly, the algebraic summation at 
low and high level is used to compute the main effects. For instance, the product 
of the variable EPA by its LTB5 response in ng/mL is (-12.1 -14.0 +13.1 +16.0 -
5.6 -10.8 +14.9 +15.6), the average at low and high levels are -10.625 and +14.9, 
and their algebraic summation is 4.275. The interaction effects are calculated in 
the same fashion by taking firstly the product between variables and the resulting 
column by the response. For instance the interaction between AA and EPA is 
calculated by AA × EPA × response. 
The main effects and their interactions for the different metabolites considered in 
the present study are presented in Table 5 and 6. 
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Table 5. Calculated main effects of AA, EPA and inhibitor towards Eicosanoid 
production 
Metabolites 
Main effects 
AA EPA INH 
PGE2 1.2 7.1 2.9 
PGE3 -5.4 18.8 5.8 
LTB4 -6.4 249.6 88.5 
LTB5 2.7 4.3 -2.0 
 
 
 
Table 6. Calculated interactive effects of AA, EPA and inhibitor towards 
Eicosanoid production. 
Metabolites 
Interaction Effects 
AE AI EI AEI 
PGE2 3.0 -0.2 1.5 1.8 
PGE3 -3.7 -11.6 5.0 -5.6 
LTB4 -4.9 -11.9 71.6 -6.3 
LTB5 -0.9 0.3 2.8 -1.3 
 
 
4.3.3 Main and interaction effects analysis 
The analyses of the different treatments (Table 4) were carried out in random 
order. After conducting the analyses and calculating the analytical concentration 
of each metabolite, the responses (ng/mL) were entered in the Minitab 15.1.30.0 
statistical software (Minitab® Inc, PA, USA).  
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4.3.3.1 PGE2 Synthesis 
The main effects of the variables on the production of PGE2 by non-parenchymal 
rat liver cells are portrayed in Fig. 21. Based on the steepness of the line 
connecting the PGE2 mean response without (-) and with (+), it is evident that the 
presence of EPA or inhibitor favored the synthesis of PGE2 when compared to 
the AA or inhibitor. However, it must be said that the observed changes in PGE2 
concentration and consequently the main effect of these variables are not 
significant at a confidence level of 95 %. The small increment of PGE2 
concentration could be ascribed either to the stress of the cells due to the 
presence of added EPA or to the release of AA from the cell membrane when 
EPA is incorporated.  
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Figure 21. Main Effects Plots of AA, EPA and Inhibitor on PGE2 Synthesis 
 
The two-factor interaction plots (Fig. 22) define the interaction of AA vs EPA 
(upper left side plot), AA vs inhibitor (upper right side plot), and EPA vs inhibitor 
(lower right side plot). The black line indicates the lower level of the variable 
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present which is equivalent to the absence of the given variable. Conversely, the 
red line signifies the level of the variable at the higher level (presence of 
variable). A strong interaction exists when the slopes of the red and black lines 
are significantly different. A small variation between slopes indicates a minimal 
interaction while symmetrical slopes indicate no interaction. Based on the 
interaction plots (Fig.13) it is evident that the degree of interaction in decreasing 
order of magnitude is EPA-AA > EPA-Inhibitor > AA-Inhibitor. The strong 
interaction EPA-AA could indicate that EPA causes stress to the membrane 
resulting in the release of free AA from the phospholipid bilayers and 
consequently activating the COX enzyme to act on AA to produce PGE2 as the 
breakdown product. The minor interaction EPA-inhibitor and AA-inhibitor reflect 
the lack of activity of the inhibitor towards the blocking of the enzymes 
responsible for the production of PGE2. 
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Figure 22. Interaction Effects Plots of AA, EPA and inhibitor on PGE2 Synthesis 
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4.3.3.2 PGE3 Synthesis 
Fig. 23 illustrates the main effects of AA, EPA and inhibitor with respect to the 
production of PGE3 in the non-parenchymal cell culture. Of the three variables, it 
is evident that the PGE3 level increased significantly with the addition of EPA into 
the culture media (upper right side plot). Thus, it can be inferred that the 
presence of EPA in the cell culture media might have enhanced the synthesis of 
PGE3 via the COX pathway. In the main effect plots of AA (upper left plot) and 
inhibitor (lower left plot), the AA (-1.9 units) and inhibitor (2.3 units) exhibit almost 
a similar effect magnitude towards the production of PGE3 but with different 
directions. The presence of AA tends to lower the production of PGE3 while 
inhibitor tends to increase the level of PGE3. This implies that the EPA is the 
precursor molecule primarily responsible in the synthesis of PGE3. However, the 
minimal positive effect of the inhibitor on the synthesis of PGE3 was unexpected. 
Thus, the interaction plot will further evaluate how inhibitor behaves with respect 
to EPA and AA in relation to the synthesis of PGE3 metabolite. 
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Figure 23. Main Effects Plot of AA, EPA and Inhibitor on PGE3 Synthesis 
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Fig. 24 shows the interaction plot of the three variables with respect to the 
synthesis of PGE3. The upper left side plot is the interactive effect between AA 
and EPA, upper right side is the interactive effect of AA and inhibitor and the 
lower right side plot for the interactive effect between EPA and inhibitor. In the 
plot, the black line indicates EPA or AA at lower level (absent) while the black 
line signifies EPA or AA at higher level (present). A significant interaction 
between AA and inhibitor is indicated by the non-parallelism of the lines in the 
plot. In the absence of AA in non-parenchymal cell culture, an increase in the 
mean PGE3 level is obtained when inhibitor is incorporated to the cell culture 
system while the opposite happens when inhibitor is added in the presence of AA 
in the cell cultures. The mean level of PGE3 tends to decrease in cell culture with 
AA when the inhibitor is added to the cell culture media. For the interaction 
between EPA and inhibitor, it can be inferred that there is a minimal interaction, 
as indicated by the slight difference in the slope of the line for non-parenchymal 
cell culture media containing EPA and non-parenchymal cell culture without EPA. 
In the case of AA vs EPA, a lack of interaction between the AA and EPA effects 
due to the parallelism of the lines in the plot. The level of PGE3 present in the 
system is primarily due to the presence of EPA. This indicates that AA does not 
inhibit EPA in the access of COX enzymes responsible for the production of 
PGE3. 
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Figure 24. Interaction Effects Plot of AA, EPA and inhibitor on PGE3 Synthesis 
 
4.3.3.3 LTB4 Synthesis 
Leukotrine B4 is an arachidonic derived eicosanoid via the lipoxygenase 
pathway. The production of this metabolite is dependent upon its precursor 
molecules, AA and EPA, which could compete with each other in the eicosanoid 
synthesis. The main effects of AA, EPA and inhibitor on LTB4 production are 
described in Fig 25.. In the plot of EPA (upper right side) a dramatic increase of 
LTB4 is achieved in the presence of EPA. Also, the cell culture media added with 
EPA produce the highest LTB4 after incubation. Inhibitor main effect plot (lower 
right side) suggests also a positive main effect on the LTB4 synthesis at a 
minimal level which indicates that perhaps the  particular  inhibitor used in the 
present experiments lacks the ability to block effectively the action of COX and 
PLA2 enzymes. Unexpectedly, the presence of AA in the cell culture media does 
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not seem to manifest any effect in the production of LTB4 metabolites but 
apparently, the presence of EPA shows to have the greatest influence.  
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Figure 25. Main Effects Plots of AA, EPA and Inhibitor on LTB4 Synthesis. 
 
The interaction effects of AA vs EPA, AA vs inhibitor and EPA vs inhibitor with 
respect to LTB4 production is portrayed in Fig. 26. The evaluation of the the plots, 
revealed a strong interaction effect between EPA and inhibitor (lower right side 
plot). It shows that an apparent increase of LTB4 production by cells happen 
when an inhibitor is added to the cell culture media treatment containing EPA. 
The main features from the three plots (Fig 26) are:  1) EPA increases 
considerably the LTB4 production with or without AA. 2) The combined term EPA 
and inhibitor indicated that the increase of LTB4 production occurs only when 
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EPA is present. 3) The combined term AA and inhibitor increased the production 
of LTB4. Based on the aforementioned observations, it can be hypothesized that 
EPA enhances the production of LTB4 in non-parenchymal rat liver cells due to 
the replacement of AA for EPA in the phospholipid membrane. The released AA 
can be metabolized into LTB4. This explanation is not found in any published 
report, however experiments with head-kidney cells from Atlantic cod and 
discussed below (Section 4.3) seem to confirm this hypothesis. 
A comparison between the main effects plots for PGE2 and LTB4 (Figs 21 & 25) 
indicate that the three factors have similar behaviors. It follows that in the 
synthesis of arachidonic acid-derived eicosanoids, EPA has the strongest 
influence over the level of metabolite produced. 
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Figure 26. Interaction Effects Plots of AA, EPA and inhibitor on LTB4 Synthesis. 
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4.3.3.4 LTB5 Synthesis 
The three factors studied had an influence on the production of LTB5 (Fig. 27). 
The effects of AA, EPA and inhibitor were similar. That is, the line containing the 
mean response for the absence and presence of AA has a slope similar to the 
slopes of the lines connecting the mean response for the presence and absence 
of EPA and the mean response for treatments with and without inhibitor. The plot 
(Fig. 27) also shows that adding EPA or AA to the various treatments bring about 
an increase in LTB5 production,  while introducing the inhibitor into the cell 
culture system causes a decreasing in  the amount of LTB5.  
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Figure 27. Main Effects Plots of AA, EPA and Inhibitor on LTB5 Synthesis. 
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The interaction plot is used to further evaluate the combined effects of the 
variables. Fig. 28 indicates the interaction between EPA and inhibitor, AA and 
EPA and AA and inhibitor.  The plot of EPA vs inhibitor (lower right) 
demonstrates that in the synthesis of LTB5, the inhibitor has a great influence in 
the decrease of LTB5 response when the cell culture media is not treated with 
EPA. In the presence of EPA, the addition of inhibitor elevates the amount of 
LTB5 produced. The increasing levels of eicosanoid in the presence of inhibitor 
could indicate that the inhibitor in question is not appropriate for studying the 
blockage of COX/PLA2 enzymes in experiments involving non-parenchymal cells. 
With respect to AA vs EPA, both treatments enhance the production of LTB5. 
But, the presence of both AA and EPA produce a much higher amount of LTB5 
as compared with the treatment without AA. From this interaction effects, it can 
be deduced that EPA has a strong influence in the synthesis of LTB5.  
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Figure 28. Interaction Effects Plots of AA, EPA and inhibitor on LTB5 Synthesis 
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4.4 Eicosanoids Synthesis in Cod Kidney Cells 
The unexpected production of AA-derived derived metabolites in the presence of 
EPA prompted the determination of eicosanoid metabolites using another type of 
cells to confirm the results. Cod kidney cells treated with EPA, AA and control 
(plain media) were used to confirm the previously discussed results. Fig. 29-32 
show the behavior of eicosanoid metabolites in cell culture media treated with AA 
and EPA. It was found that there is significant increase in the levels of PGE2 (p = 
0.0038) and LTB4 (p = 0.0010) when AA is present in the cell culture media as 
compared with the cell culture containing AA. This indicates the EPA may have 
some role in the synthesis of AA-derived metabolites not reported yet in dietary 
studies. Conversely, in cell media treated with AA no significant increase in EPA-
derived metabolites was found. This suggests the AA has no influence over the 
synthesis of PGE3 and LTB5. 
 
 
 
 
Figure 29. PGE2 Production from Cod Kidney Cells 
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Figure 30. PGE3 Production from Cod Kidney Cells 
 
 
 
 
 
Figure 31. LTB4 Production from Cod Kidney Cells 
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Figure 32. LTB5 Production from Cod Kidney Cells 
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Chapter 5 
CONCLUDING REMARKS 
 
A significant increase in the production of LTB4 in the presence of EPA indicates 
that EPA seems to have a strongest influence in the production of pro-
inflammatory LOX associated metabolites. The elevated production of LTB4 as a 
result of adding EPA could be rationalized as the replacement of AA for EPA in 
the phospholipid membrane and subsequently metabolization of the released AA 
into the proinflammatory LTB4. It must be said that this is the first ever report that 
has observed such increase in the production of LTB4 in the presence of EPA. 
However, it would be advisable to carry on studying systematically different kinds 
of cell cultures and AA and EPA concentrations in order to fully clarify the role of 
these essential fatty acids. 
 
The minimal increase of the production of PGE2 in the cell culture media 
indicates that the inhibitor used in the study lacks the ability to block the action of 
PLA2 and COX enzymes. It would be advisable to use in a more effective 
inhibitor in future experiments. 
 
The experimental evidence by using two different kinds of cell cultures 
(mammalian and fish) showed that the LOX pathway is favoured in in vitro 
experiments involving EPA and AA. Although a similar behavior was observe for 
the two types of cells tested, It is unclear why the LOX pathway is preferred. 
 
The application of MS Resolver™ in the LCMS data set from AA and EPA 
derived metabolites demonstrated to be an important tool that can assist in the 
quantification of overlapping metabolites. The generated chromatograms 
obtained by MS Resolver™ are easy to quantify. 
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